Neutral
Boston Scientific's 2026 Annual Meeting highlighted its strong 2025 performance, including $20 billion in net sales and over $2 billion invested in R&...
Bullish
Boston Scientific Corporation (BSX) is considered a top medical device stock, despite recent price target cuts from Argus and Truist. Analysts maintai...
Neutral
Calamos Wealth Management LLC decreased its stake in Boston Scientific Corporation by 24.4% in the fourth quarter, reducing its holdings to 117,214 sh...
Neutral
Stifel has lowered its price target for Boston Scientific Corp. (NYSE:BSX) to $85 from $90, while maintaining a Buy rating, ahead of the company's Q1 ...
Neutral
Stifel lowered its price target for Boston Scientific Corp. (NYSE:BSX) to $85 from $90, while maintaining a Buy rating. The adjustment was based on mo...
Bearish
Truist has lowered its price target for Boston Scientific Corporation (BSX) to $90 from $92, while maintaining a Buy rating. This adjustment reflects ...
Neutral
Sumitomo Mitsui Trust Group Inc. reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 3.3% during the fourth quart...